Noreen Scherer
Chief Tech/Sci/R&D Officer chez LARIMAR THERAPEUTICS, INC.
Profil
Noreen Scherer is currently the Vice President-Clinical Operations at Larimar Therapeutics, Inc. and Alcobra, Inc. She previously held the same position at Chondrial Therapeutics, Inc. Ms. Scherer completed her undergraduate degree at LaSalle University.
Postes actifs de Noreen Scherer
| Sociétés | Poste | Début |
|---|---|---|
| LARIMAR THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/05/2018 |
| Alcobra, Inc. | Chief Operating Officer | - |
Anciens postes connus de Noreen Scherer
| Sociétés | Poste | Fin |
|---|---|---|
Chondrial Therapeutics, Inc.
 Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Chief Tech/Sci/R&D Officer | - |
Formation de Noreen Scherer
| LaSalle University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LARIMAR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Chondrial Therapeutics, Inc.
Chondrial Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Chondrial Therapeutics, Inc. operates as a biotechnology company which focuses on the treatment of rare mitochondrial diseases. Its compound is CTI-1601, which the company is developing as a potential treatment for Friedreich’s Ataxia. The company was founded by Steven R. Plump and Mark R. Payne and is headquartered in Bala Cynwyd, PA. | Health Technology |
| Alcobra, Inc. |
